These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 26036314

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ, Wang ZJ, De W, Zheng M, Xu WZ, Wu HF, Armstrong A, Zhu JG.
    Oncotarget; 2017 Jun 20; 8(25):41064-41077. PubMed ID: 28455956
    [Abstract] [Full Text] [Related]

  • 3. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.
    Mol Cancer Ther; 2013 Nov 20; 12(11):2541-58. PubMed ID: 24026012
    [Abstract] [Full Text] [Related]

  • 4. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY, Lee HY, Lee C.
    Int J Oncol; 2015 Jul 20; 47(1):353-60. PubMed ID: 25975389
    [Abstract] [Full Text] [Related]

  • 5. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL.
    Cancer Res; 2021 Mar 01; 81(5):1398-1412. PubMed ID: 33402388
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
    Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.
    Mol Cancer Ther; 2019 Feb 01; 18(2):389-398. PubMed ID: 30478151
    [Abstract] [Full Text] [Related]

  • 7. Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma.
    Hong J, Maacha S, Belkhiri A.
    Mol Oncol; 2018 Dec 01; 12(12):2191-2208. PubMed ID: 30353671
    [Abstract] [Full Text] [Related]

  • 8. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
    Lin JZ, Zhu JG, Wu HF, Li JM, DE W, Wang ZJ.
    Zhonghua Nan Ke Xue; 2017 Apr 01; 23(4):302-308. PubMed ID: 29714413
    [Abstract] [Full Text] [Related]

  • 9. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM, Min KJ, Seo SU, Kim S, Kubatka P, Park JW, Kwon TK.
    Int J Mol Sci; 2019 Jul 02; 20(13):. PubMed ID: 31269715
    [Abstract] [Full Text] [Related]

  • 10. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S.
    Oncotarget; 2015 Jun 30; 6(18):16183-97. PubMed ID: 25980499
    [Abstract] [Full Text] [Related]

  • 11. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
    Scherschinski L, Prem M, Kremenetskaia I, Tinhofer I, Vajkoczy P, Karbe AG, Onken JS.
    Int J Mol Sci; 2022 Jan 17; 23(2):. PubMed ID: 35055167
    [Abstract] [Full Text] [Related]

  • 12. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y.
    Cancer Res; 2010 Feb 15; 70(4):1544-54. PubMed ID: 20145120
    [Abstract] [Full Text] [Related]

  • 13. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
    Wang C, Jin H, Wang N, Fan S, Wang Y, Zhang Y, Wei L, Tao X, Gu D, Zhao F, Fang J, Yao M, Qin W.
    Theranostics; 2016 Feb 15; 6(8):1205-19. PubMed ID: 27279912
    [Abstract] [Full Text] [Related]

  • 14. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.
    Clin Cancer Res; 2015 Jun 01; 21(11):2601-12. PubMed ID: 25767293
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.
    Mol Cancer Ther; 2017 Dec 01; 16(12):2881-2891. PubMed ID: 28904132
    [Abstract] [Full Text] [Related]

  • 16. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.
    Sci Signal; 2016 Oct 04; 9(448):ra97. PubMed ID: 27703030
    [Abstract] [Full Text] [Related]

  • 17. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S.
    Int J Mol Sci; 2016 Dec 22; 18(1):. PubMed ID: 28025482
    [Abstract] [Full Text] [Related]

  • 18. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
    Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, Gray NS, George RE.
    Oncogene; 2016 Jul 14; 35(28):3681-91. PubMed ID: 26616860
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
    Tian M, Chen XS, Li LY, Wu HZ, Zeng D, Wang XL, Zhang Y, Xiao SS, Cheng Y.
    Acta Pharmacol Sin; 2021 Jul 14; 42(7):1180-1189. PubMed ID: 33149145
    [Abstract] [Full Text] [Related]

  • 20. Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis.
    Zhen Y, Lee IJ, Finkelman FD, Shao WH.
    J Autoimmun; 2018 Sep 14; 93():37-44. PubMed ID: 29895432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.